Literature DB >> 35450189

Transgenic dry eye mouse models: powerful tools to study dry eye disease.

Dan-Yi Qin1, Li-Xiang Wang1, Ying-Ping Deng1.   

Abstract

Dry eye disease (DED) is one of the most common chronic multifactorial ocular surface diseases with high prevalence and complex pathogenesis. DED results in several ocular discomforts, vision fluctuation, and even potential damage of the ocular surface, bringing heavy burdens both on individuals and the society. The pathology of DED consists of tear film hyperosmolarity and immune responses on the ocular surface. Mice are widely used for developing models that simulate human DED features for investigating its pathogenesis and treatment. DED can be classified into aqueous-deficiency dry eye (ADDE) and evaporative dry eye (EDE). ADDE can be further divided into Sjögren syndrome dry eye (SSDE) and non-Sjögren syndrome dry eye (NSSDE). SSDE mouse models include natural strains, typified by non-obese diabetic (NOD) mice, and genetically engineered ones, like Aire-/- and Id3 knockout mice. Intrinsic EDE mainly refers to meibomian gland dysfunction (MGD). Eda-/- Tabby, Sod1-/-, Elovl1-/- are the most common transgenic MGD mouse models. Transgenic mouse models provide useful tools for studying the pathogenesis of DED and evaluating its novel therapies. This review compares the major transgenic dry eye mouse models and discusses their applications in DED research. International Journal of Ophthalmology Press.

Entities:  

Keywords:  dry eye disease; mouse models; ocular surface; pathology; transgenic

Year:  2022        PMID: 35450189      PMCID: PMC8995740          DOI: 10.18240/ijo.2022.04.18

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  104 in total

1.  The Role of 2% Rebamipide Eye Drops Related to Conjunctival Differentiation in Superoxide Dismutase-1 (Sod1) Knockout Mice.

Authors:  Takashi Kojima; Cem Simsek; Ayako Igarashi; Kazue Aoki; Kazunari Higa; Takahiko Shimizu; Murat Dogru; Kazuo Tsubota; Jun Shimazaki
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-01       Impact factor: 4.799

2.  Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older.

Authors:  Kimberly F Farrand; Moshe Fridman; Ipek Özer Stillman; Debra A Schaumberg
Journal:  Am J Ophthalmol       Date:  2017-07-10       Impact factor: 5.258

3.  Age-Related Conjunctival P2Y2 Receptor Alterations in the Cu, Zn-Superoxide Dismutase-1 (Sod1)-Knockout Dry Eye Model Mice.

Authors:  Murat Dogru; Megumi Shinzawa; Takashi Kojima; Takahiko Shimizu; Kazuo Tsubota
Journal:  Eye Contact Lens       Date:  2019-11       Impact factor: 2.018

4.  IL-4-STAT6 signal transduction-dependent induction of the clinical phase of Sjögren's syndrome-like disease of the nonobese diabetic mouse.

Authors:  Cuong Q Nguyen; Jue-hua Gao; Hyuna Kim; Daniel R Saban; Janet G Cornelius; Ammon B Peck
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

5.  Deficiency of Act1, a critical modulator of B cell function, leads to development of Sjögren's syndrome.

Authors:  Youcun Qian; Natalia Giltiay; Jianhua Xiao; Yue Wang; Jun Tian; Shuhua Han; Martin Scott; Robert Carter; Trine N Jorgensen; Xiaoxia Li
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

6.  Fingolimod reduces salivary infiltrates and increases salivary secretion in a murine Sjögren's model.

Authors:  Philip L Cohen; Amanda McCulloch
Journal:  J Autoimmun       Date:  2020-10-13       Impact factor: 7.094

7.  Lack of T cells in Act1-deficient mice results in elevated IgM-specific autoantibodies but reduced lupus-like disease.

Authors:  Angela C Johnson; Laura M Davison; Natalia V Giltiay; Chairut Vareechon; Xiaoxia Li; Trine N Jørgensen
Journal:  Eur J Immunol       Date:  2012-07       Impact factor: 5.532

8.  Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease.

Authors:  Trinka Vijmasi; Feeling Y T Chen; Ying Ting Chen; Marianne Gallup; Nancy McNamara
Journal:  Mol Vis       Date:  2013-09-19       Impact factor: 2.367

9.  Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome.

Authors:  Zhen Meng; Wannita Klinngam; Maria C Edman; Sarah F Hamm-Alvarez
Journal:  PLoS One       Date:  2017-09-13       Impact factor: 3.240

10.  Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients.

Authors:  Maria C Edman; Srikanth R Janga; Zhen Meng; Mercy Bechtold; Alexander F Chen; Chongiin Kim; Luke Naman; Arunava Sarma; Neha Teekappanavar; Alice Y Kim; Sara Madrigal; Simranjit Singh; Elizabeth Ortiz; Stratos Christianakis; Daniel G Arkfeld; Wendy J Mack; Martin Heur; William Stohl; Sarah F Hamm-Alvarez
Journal:  Sci Rep       Date:  2018-07-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.